We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Implantable Nerve Stimulator Helps Alleviate OSA Symptoms

By HospiMedica International staff writers
Posted on 21 Jun 2016
Innovative hypoglossal nerve stimulation (HGNS) implants offers promise for patients with moderate to severe obstructive sleep apnea (OSA).

Researchers at the University of Pennsylvania (Penn; Philadelphia, USA) conducted a study involving 20 patients who were implanted with the Inspire Upper Airway Stimulation device, as they were unable to tolerate continuous positive airway pressure (CPAP) treatment for OSA. More...
All patients had information from a baseline polysomnography (PSG) recording prior to HGNS implant and again approximately two months after HGNS in order to assess the severity of their apnea and any change after treatment. Those who received the implant were typically overweight, middle aged, and had severe OSA.

The results showed that total apnea-hypopnea index (AHI)--which measures severity of sleep apnea by counting the number of pauses in breathing during sleep--for all patients significantly decreased an average of 35 events per hour after the device was planted, which corresponds to an average reduction of 84%. Additionally, the lowest oxygen level measured in the blood during the night significantly increased by 11%, from 79% to 90%. The study was presented at the 30th annual meeting of the Associated Professional Sleep Societies (SLEEP), held during June 2016 in Denver (CO, USA).

“Considering that sleep apnea can lead to high blood pressure, heart attack, stroke, and other serious health problems, it is critically important that we study devices that may serve as another option instead of CPAP to treat patients with sleep apnea,” said lead author Richard Schwab, MD, co-medical director of the Penn Sleep Center. “There is no perfect treatment option for obstructive sleep apnea, but our preliminary data suggest that hypoglossal nerve stimulation can effectively treat patients with sleep apnea who are unable to tolerate CPAP.”

The Inspire Upper Airway Stimulation device, a product of Inspire Medical Systems (Maple Grove, MN, USA), is a pacemaker with a tiny generator and a sensing lead to stimulate the tongue. Patients use a remote control to turn on the device before going to sleep and turn it off upon waking up. A delay allows the user to fall asleep before the pulse generator begins stimulation. After detecting the user's breathing pattern, the machine stimulates the hypoglossal nerve, which controls tongue motion to enlarge the upper airway.

Related Links:
University of Pennsylvania
Inspire Medical Systems

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Fetal Monitor
BT-380
Rapid Sepsis Test
SeptiCyte RAPID
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image: Clinical LLM Performance Improves by >300% When Provided with High-Quality Real-World Evidence in New Precision Medicine Benchmark (Photo courtesy of Atropos Health)

New Benchmark Highlights Evidence Gaps in AI Responses to Clinical Questions

Many clinical decisions still rely on limited evidence, while most artificial intelligence benchmarks overlook the patient context that shapes real-world care. General large language models can also struggle... Read more

Critical Care

view channel
Image Credit: 123RF

AI Platform Screens for Amyloid Cardiomyopathy Using ECG Images

Amyloid cardiomyopathy is a heart disease caused by deposits of misfolded proteins in the cardiac muscle. It is often missed until patients develop serious complications such as heart failure.... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: LigaSure RAS Maryland, designed for the Valleylab FT10 platform on Hugo RAS, seals and cuts vessels, tissue, and lymphatics up to 7 mm in diameter (Photo courtesy of Medtronic)

Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery

As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.